JP5586815B2 - 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 - Google Patents
乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 Download PDFInfo
- Publication number
- JP5586815B2 JP5586815B2 JP2003572638A JP2003572638A JP5586815B2 JP 5586815 B2 JP5586815 B2 JP 5586815B2 JP 2003572638 A JP2003572638 A JP 2003572638A JP 2003572638 A JP2003572638 A JP 2003572638A JP 5586815 B2 JP5586815 B2 JP 5586815B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- composition
- milk
- weight
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims description 96
- 235000013336 milk Nutrition 0.000 title claims description 46
- 239000008267 milk Substances 0.000 title claims description 46
- 210000004080 milk Anatomy 0.000 title claims description 46
- 229910052500 inorganic mineral Inorganic materials 0.000 title claims description 41
- 239000011707 mineral Substances 0.000 title claims description 41
- 238000000034 method Methods 0.000 title description 15
- 230000037396 body weight Effects 0.000 title description 7
- 239000005018 casein Substances 0.000 title description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title description 2
- 235000021240 caseins Nutrition 0.000 title description 2
- 239000011575 calcium Substances 0.000 claims description 50
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 49
- 229910052791 calcium Inorganic materials 0.000 claims description 49
- 235000015872 dietary supplement Nutrition 0.000 claims description 30
- 108010076119 Caseins Proteins 0.000 claims description 21
- 102000011632 Caseins Human genes 0.000 claims description 21
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 235000021246 κ-casein Nutrition 0.000 claims description 20
- 108010046377 Whey Proteins Proteins 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 102000007544 Whey Proteins Human genes 0.000 claims description 10
- 235000012054 meals Nutrition 0.000 claims description 10
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 8
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 8
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 8
- 239000005862 Whey Substances 0.000 claims description 6
- 101710178392 Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 claims description 2
- 229960005069 calcium Drugs 0.000 description 47
- 235000010755 mineral Nutrition 0.000 description 38
- 208000008589 Obesity Diseases 0.000 description 21
- 235000020824 obesity Nutrition 0.000 description 21
- 206010033307 Overweight Diseases 0.000 description 19
- 235000013305 food Nutrition 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 235000016709 nutrition Nutrition 0.000 description 14
- 235000013361 beverage Nutrition 0.000 description 13
- 239000011777 magnesium Substances 0.000 description 12
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 11
- 229910052749 magnesium Inorganic materials 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 10
- 108090000790 Enzymes Proteins 0.000 description 10
- 229940088598 enzyme Drugs 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 235000013365 dairy product Nutrition 0.000 description 9
- 230000004580 weight loss Effects 0.000 description 9
- 230000037221 weight management Effects 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 101800001982 Cholecystokinin Proteins 0.000 description 8
- 102100025841 Cholecystokinin Human genes 0.000 description 8
- 229940107137 cholecystokinin Drugs 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 7
- 230000036186 satiety Effects 0.000 description 7
- 235000019627 satiety Nutrition 0.000 description 7
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 6
- 210000001789 adipocyte Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000011574 phosphorus Substances 0.000 description 6
- 229910052698 phosphorus Inorganic materials 0.000 description 6
- 235000004252 protein component Nutrition 0.000 description 6
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 235000021119 whey protein Nutrition 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000011591 potassium Substances 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011701 zinc Substances 0.000 description 4
- 229910052725 zinc Inorganic materials 0.000 description 4
- 235000004251 balanced diet Nutrition 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 239000001527 calcium lactate Substances 0.000 description 3
- 229960002401 calcium lactate Drugs 0.000 description 3
- 235000011086 calcium lactate Nutrition 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- 108010067454 caseinomacropeptide Proteins 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 235000015111 chews Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000000378 dietary effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000012631 food intake Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000036449 good health Effects 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000001717 Vaccinium macrocarpon Species 0.000 description 2
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 2
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 235000015197 apple juice Nutrition 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 235000008429 bread Nutrition 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 235000020303 café frappé Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 235000014510 cooky Nutrition 0.000 description 2
- 235000004634 cranberry Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 235000005686 eating Nutrition 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000019674 grape juice Nutrition 0.000 description 2
- 235000015201 grapefruit juice Nutrition 0.000 description 2
- 235000004280 healthy diet Nutrition 0.000 description 2
- 235000015243 ice cream Nutrition 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 235000014058 juice drink Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000004132 lipogenesis Effects 0.000 description 2
- 230000004130 lipolysis Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000020166 milkshake Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000012459 muffins Nutrition 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000015205 orange juice Nutrition 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000014059 processed cheese Nutrition 0.000 description 2
- 235000013570 smoothie Nutrition 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 235000013322 soy milk Nutrition 0.000 description 2
- 235000011496 sports drink Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 235000013618 yogurt Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000004881 Angiotensinogen Human genes 0.000 description 1
- 108090001067 Angiotensinogen Proteins 0.000 description 1
- 101001099470 Bos taurus Lactoperoxidase Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010006956 Calcium deficiency Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003706 Complement factor D Human genes 0.000 description 1
- 108090000059 Complement factor D Proteins 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 206010021027 Hypomagnesaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 102000045576 Lactoperoxidases Human genes 0.000 description 1
- 102000016267 Leptin Human genes 0.000 description 1
- 108010092277 Leptin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 229940069978 calcium supplement Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000020509 fortified beverage Nutrition 0.000 description 1
- 235000014106 fortified food Nutrition 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000037219 healthy weight Effects 0.000 description 1
- 235000021098 high calorie intake Nutrition 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940057428 lactoperoxidase Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940039781 leptin Drugs 0.000 description 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000021097 low calorie intake Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009064 short-term regulation Effects 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C21/00—Whey; Whey preparations
- A23C21/02—Whey; Whey preparations containing, or treated with, microorganisms or enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/185—Vegetable proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Mycology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Pain & Pain Management (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
Description
本出願は2002年3月1日出願の「肥満の治療のための組成物および方法(compositions and Methods for Treatment of Obesity)」と題した同時係属中の米国仮出願番号第60/360,709号、並びに2003年2月21日出願の「体重状態の治療のための組成物および方法(Compositions and Methods for Treatment of Body Weight Conditions)」と題した同時係属中の米国出願の利益に基づき、そしてそれを主張し、その開示を出展明示により本明細書の一部とする。
本発明は、治療上有効な栄養補助組成物(nutritional supplement composition)を投与することにより、体重状態を治療するための組成物および方法を志向する。具体的には、乳鉱物(milk mineral)混合物およびタンパク質成分を含む栄養組成物は体重減少の増強および/または体重増加の制限に有効である。
BMI=体重(kg)/[身長(m)]2
この実施例は栄養補助組成物で強化した飲料の調製を説明する。成分を混合して表2に示す組成を有する製品を作製した。
この実施例は栄養補助組成物で強化した第1の粉末飲料混合物の処方を説明する。成分を混合して表3に示す組成を有する製品を作製した。
この実施例は栄養補助組成物で強化した第2の粉末飲料混合物の処方を説明する。成分を混合して表4に示す組成を有する製品を作製した。
この実施例は栄養補助組成物で強化した第3の粉末飲料混合物の処方を説明する。成分を混合して表5に示す組成を有する製品を作製した。
Claims (5)
- 下表に示す組成の乳鉱物混合物と、
κ−カゼインフラグメント106−169と、
アンジオテンシン変換酵素阻害ペプチドと
を含み、
一人分あたり0.5〜6グラムのカルシウム、3〜10グラムのκ−カゼインフラグメント106−169、及び1〜20グラムのアンジオテンシン変換酵素阻害ペプチドを含み、該カルシウムは該乳鉱物混合物由来である組成物を含む、栄養補助食品。
- κ−カゼインフラグメント106−169が、牛乳由来、乳清由来又はその組み合わせである、請求項1記載の組成物。
- 乾燥粉末の形態である、請求項1又は2記載の組成物。
- 前記組成物は食間に投与される、請求項1〜3のいずれか1項記載の組成物。
- 前記組成物は食事の一部として投与される、請求項1〜3のいずれか1項記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36070902P | 2002-03-01 | 2002-03-01 | |
US60/360,709 | 2002-03-01 | ||
US10/371,534 | 2003-02-21 | ||
US10/371,534 US20030165574A1 (en) | 2002-03-01 | 2003-02-21 | Compositions and methods for treatment of body weight conditions |
PCT/US2003/005797 WO2003074129A1 (en) | 2002-03-01 | 2003-02-25 | Compositions and methods for treatment of body weight conditions with milk minerals and casein fractions |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010089453A Division JP6041459B2 (ja) | 2002-03-01 | 2010-04-08 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006507217A JP2006507217A (ja) | 2006-03-02 |
JP5586815B2 true JP5586815B2 (ja) | 2014-09-10 |
Family
ID=27789006
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003572638A Expired - Lifetime JP5586815B2 (ja) | 2002-03-01 | 2003-02-25 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
JP2010089453A Expired - Fee Related JP6041459B2 (ja) | 2002-03-01 | 2010-04-08 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
JP2014001185A Pending JP2014097997A (ja) | 2002-03-01 | 2014-01-07 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010089453A Expired - Fee Related JP6041459B2 (ja) | 2002-03-01 | 2010-04-08 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
JP2014001185A Pending JP2014097997A (ja) | 2002-03-01 | 2014-01-07 | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 |
Country Status (10)
Country | Link |
---|---|
US (3) | US20030165574A1 (ja) |
EP (3) | EP2374507A1 (ja) |
JP (3) | JP5586815B2 (ja) |
KR (2) | KR20040105737A (ja) |
CN (1) | CN1649644A (ja) |
AU (1) | AU2003213291A1 (ja) |
BR (1) | BR0308141A (ja) |
CA (1) | CA2477854C (ja) |
MX (1) | MXPA04008476A (ja) |
WO (1) | WO2003074129A1 (ja) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030118662A1 (en) * | 2001-12-05 | 2003-06-26 | Glanbia Foods, Inc. | Therapeutic uses of milk mineral fortified food products |
US20030165574A1 (en) * | 2002-03-01 | 2003-09-04 | Ward Loren Spencer | Compositions and methods for treatment of body weight conditions |
JP2005538704A (ja) * | 2002-07-01 | 2005-12-22 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 満腹誘導組成物 |
US20060171992A1 (en) * | 2002-12-20 | 2006-08-03 | Gerhardt Cinderella C | Blood glucose regulating composition |
AU2004273759A1 (en) * | 2003-09-19 | 2005-03-31 | N.V. Nutricia | Method and composition for preventing multiple organ dysfunction syndrome |
BRPI0508181A (pt) * | 2004-04-02 | 2007-08-07 | Univ Tennessee Res Foundation | componentes de laticìnio eficazes para a perda de gordura |
WO2005117933A1 (en) * | 2004-05-27 | 2005-12-15 | Campina Nederland Holding B.V. | Use of protein hydrolysates for the manufacture of a medicament for prophylaxis and/or treatment of a dpp-iv mediated condition |
EP1781116A4 (en) * | 2004-06-04 | 2009-07-29 | Horizon Science Pty Ltd | NATURAL SWEETENER |
AU2005296271A1 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
US20060210650A1 (en) * | 2004-12-14 | 2006-09-21 | Gardiner Paul T | Supplemental dietary composition for promoting weight loss |
EP1831361B1 (en) | 2004-12-23 | 2012-01-25 | Campina Nederland Holding B.V. | Protein hydrolysate enriched in peptides inhibiting dpp-iv and their use |
KR100651703B1 (ko) * | 2004-12-29 | 2006-11-29 | 박주환 | 면역 활성을 향상시키는 정제 형태의 우유 조성물 및 그제조 방법 |
AU2006235407B2 (en) * | 2005-04-11 | 2011-02-24 | University Of Tennessee Research Foundation | Stable dairy components effective for fat loss |
DE602006000787T2 (de) * | 2005-04-19 | 2009-04-16 | Unilever N.V. | Belüftete essbare Emulsion |
AU2006238853A1 (en) * | 2005-04-26 | 2006-11-02 | Ambryx Biotechnology, Inc. | Compositions and methods for treating or preventing overweight or obesity with zinc-charged protein fragments |
US8021697B2 (en) * | 2005-06-03 | 2011-09-20 | Horizon Science Pty. Ltd. | Substances having body mass redistribution properties |
DE102005033630A1 (de) * | 2005-07-19 | 2007-01-25 | Humana Gmbh | Calcium-Peptid-Komponente |
JP2009517464A (ja) | 2005-11-30 | 2009-04-30 | カンピーナ ネーダーランド ホールディング ビー.ブイ. | グルカゴン様ペプチド1の活性を増強するタンパク質加水分解物の使用 |
RU2008152756A (ru) * | 2006-06-01 | 2010-07-20 | Унилевер Н.В. (NL) | Замороженные кондитерские изделия |
EP2030629B1 (en) | 2006-06-09 | 2014-04-30 | Morinaga Milk Industry Co., Ltd. | Alpha-s-casein as lipid-metabolism-improving agent |
AU2007299581B2 (en) * | 2006-09-19 | 2011-04-28 | Poly Gain Pte Ltd | Extracts derived from sugar cane and a process for their manufacture |
ES2402978T3 (es) * | 2006-10-03 | 2013-05-13 | Unilever N.V. | Dulces congelados |
EP1915914B1 (en) * | 2006-10-03 | 2012-08-08 | Unilever PLC | Frozen confections |
DE102006052560B4 (de) * | 2006-11-06 | 2010-01-21 | Humana Milchunion Eg | Anti-diabetogene Calcium-Peptid-Zusammensetzung |
US9066536B2 (en) * | 2007-09-12 | 2015-06-30 | University Of Copenhagen | Compositions and methods for increasing the suppression of hunger and reducing the digestibility of non-fat energy satiety |
CN101228963B (zh) * | 2008-01-25 | 2011-09-28 | 上海医学生命科学研究中心有限公司 | 一种含有吡咯并喹啉醌的强化食品 |
MX2010012171A (es) * | 2008-05-21 | 2010-11-30 | Stokely Van Camp Inc | Bebida de recupercion a base de leche. |
US20110165138A1 (en) * | 2008-06-26 | 2011-07-07 | Healthlinx Limited | Protocols for treating and preventing obesity and complications arising therefrom |
US20100022442A1 (en) * | 2008-07-25 | 2010-01-28 | Ambryx Biotechnology, Inc. | Compositions and methods for increasing serum antioxidant concentrations, decreasing serum triglyceride levels, inhibiting insulin-receptor signaling activity, increasing serum ghrelin levels, and decreasing serum tnf-alpha levels |
US20130052278A1 (en) * | 2010-03-11 | 2013-02-28 | Rich Vitamins Llc | Quick dissolve nutritional powder |
BR112013002205A2 (pt) * | 2010-07-29 | 2016-05-24 | Univ Sydney | pó de suco de fruta e vegetais |
US9572852B2 (en) | 2011-02-08 | 2017-02-21 | The Product Makers (Australia) Pty Ltd | Sugar extracts |
US20130196030A1 (en) * | 2012-02-01 | 2013-08-01 | Anthony William Criezis | Dairy Products With Added Dairy Minerals And Methods Of Producing The Same |
US10849334B2 (en) | 2012-02-01 | 2020-12-01 | Koninklijke Douwe Egberts B.V. | Dairy mineral-fortified liquid dairy products and methods for making the dairy mineral-fortified liquid dairy products |
MY171216A (en) | 2012-08-28 | 2019-10-02 | The Product Makers Australia Pty Ltd | Extraction method |
AU2014306366B9 (en) | 2013-08-16 | 2020-03-26 | Poly Gain Pte Ltd | Sugar cane derived extracts and methods of treatment |
WO2016069328A1 (en) * | 2014-10-31 | 2016-05-06 | Abbott Laboratories | Nutritional compositions |
KR102073175B1 (ko) * | 2016-10-06 | 2020-02-04 | 강원대학교산학협력단 | 고지혈증 예방 또는 개선용 건강기능식품 |
JP7339650B2 (ja) * | 2019-07-22 | 2023-09-06 | 国立大学法人京都大学 | ペプチド |
CN112595683B (zh) * | 2020-12-11 | 2021-08-06 | 暮羊羊生物科技有限公司 | 一种高营养富硒羊奶制备方法及其蛋白特征肽的表征应用 |
Family Cites Families (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US4298601A (en) * | 1972-03-06 | 1981-11-03 | Technutra, S.A. | Method and formulations for the treatment of obesity |
US4081555A (en) * | 1976-06-09 | 1978-03-28 | Roger Marten | Preservation of whey |
US4497836A (en) * | 1982-08-06 | 1985-02-05 | Dairy Technology Ltd. | Modified whey product and process including ultrafiltration and demineralization |
CA1200416A (en) * | 1983-05-13 | 1986-02-11 | Societe Des Produits Nestle S.A. | Food process |
US4833128A (en) * | 1984-12-28 | 1989-05-23 | Neil Solomon | Dietary supplement |
CA2007525A1 (en) * | 1989-01-30 | 1990-07-30 | Zola P. Horovitz | Method for facilating dieting employing an ace inhibitor |
CA2026686A1 (en) * | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
JPH04316598A (ja) * | 1990-01-23 | 1992-11-06 | Snow Brand Milk Prod Co Ltd | 新規ペプチド、その塩及びこれを有効成分とする血圧降下剤 |
JPH03251543A (ja) * | 1990-02-26 | 1991-11-11 | Unitika Ltd | アンジオテンシン変換酵素阻害剤 |
EP0445606B1 (en) * | 1990-02-27 | 1997-01-22 | The Agency of Industrial Science and Technology | Novel oligopeptides, pharmaceutical composition and food containing the same, and use of oligopeptides |
JPH04154798A (ja) * | 1990-10-17 | 1992-05-27 | Snow Brand Milk Prod Co Ltd | 生理活性ペプチド及びその塩 |
JP2976349B2 (ja) * | 1990-11-29 | 1999-11-10 | 雪印乳業株式会社 | k―カゼイングリコマクロペプチドの製造法 |
JP2920427B2 (ja) * | 1991-01-21 | 1999-07-19 | 雪印乳業株式会社 | κ−カゼイングリコマクロペプチドの製造法 |
JP3091772B2 (ja) * | 1991-03-12 | 2000-09-25 | カルピス株式会社 | アンジオテンシン変換酵素阻害ペプチド組成物 |
JP3009498B2 (ja) * | 1991-03-28 | 2000-02-14 | 日清製粉株式会社 | 脂質分解酵素阻害剤 |
JP2782142B2 (ja) * | 1992-07-23 | 1998-07-30 | カルピス株式会社 | アンジオテンシン変換酵素阻害剤及びその製造法 |
JPH0825891B2 (ja) * | 1993-06-25 | 1996-03-13 | 株式会社薬理学中央研究所 | 脱脂米胚芽由来のリパーゼインヒビター |
US5625032A (en) * | 1993-07-21 | 1997-04-29 | Amylin Pharmaceuticals, Inc. | Selective amylin antagonist peptides and uses therefor |
US5855949A (en) * | 1994-01-10 | 1999-01-05 | Mclean; Linsey | Dietary system high in oil intake |
US5484623A (en) * | 1994-01-10 | 1996-01-16 | Mclean; Linsey | Dietary system high in oil intake for the treatment of obesity and for the lowering of saturated fats |
JP3398490B2 (ja) * | 1994-09-30 | 2003-04-21 | 雪印乳業株式会社 | ホエータンパク質ペプチド組成物及びその製造法 |
JP3411696B2 (ja) * | 1994-12-26 | 2003-06-03 | 明治乳業株式会社 | 乳清ミネラル組成物、該組成物の製造方法及び前記組成物の利用 |
US5639501A (en) | 1995-01-31 | 1997-06-17 | Vembu; Rajan | Separation of minerals from whey permeate |
FR2733995B1 (fr) * | 1995-05-09 | 1997-07-25 | Inst Nat Sante Rech Med | Inhibiteurs de l'inactivation de neuropeptides endogenes notamment la cholecystokinine, leurs procedes de preparation leur utilisation comme medicaments et procede de criblage de medicaments |
US5683725A (en) * | 1995-05-25 | 1997-11-04 | Biofrontiers, Inc. | Modulation of substance P by compounds containing calcium sulfate and methods relating thereto |
US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
KR0182396B1 (ko) * | 1995-06-17 | 1999-03-20 | 한동근 | 다이어트 영양 조성물 |
EP0842611A3 (en) * | 1996-11-15 | 1998-07-22 | Kyowa Hakko Kogyo Kabushiki Kaisha | A whey mineral of high zinc content |
FI120290B (fi) * | 1996-12-30 | 2009-09-15 | Mirador Res Oy Ltd | Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia |
JP2002502814A (ja) * | 1997-10-31 | 2002-01-29 | チルドレンズ・メディカル・センター・コーポレイション | 血管化した正常組織の大きさおよび増殖の調節のための方法 |
AUPP051497A0 (en) * | 1997-11-24 | 1997-12-18 | University Of Melbourne, The | Antimicrobial peptides |
US6106874A (en) * | 1998-11-18 | 2000-08-22 | Abbott Laboratories | Calcium fortified juice-based nutritional supplement and process of making |
WO2000041572A1 (fr) * | 1999-01-11 | 2000-07-20 | Calpis Co., Ltd. | Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum |
US6558716B1 (en) * | 1999-01-14 | 2003-05-06 | Kraft Foods Holdings, Inc. | Process for incorporating whey protein into cheese |
FR2788526B1 (fr) * | 1999-01-20 | 2002-07-05 | Inst Nat Sante Rech Med | Composes tripeptidiques utiles a titre d'hinhibiteurs selectifs de l'aminopeptidase a et compositions pharmaceutiques correspondantes |
US6340669B1 (en) * | 1999-01-22 | 2002-01-22 | Hunza Di Maria Carmela Marazzita S.A.S. | Lipoprotein complexes and compositions containing them |
US6312755B1 (en) * | 1999-07-16 | 2001-11-06 | Ampc | Whey treatment process for achieving high concentration of α-lactalbumin |
US6403657B1 (en) * | 1999-10-04 | 2002-06-11 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity |
AU2001241558A1 (en) * | 2000-02-21 | 2001-09-03 | Larry R. Russell | Method and apparatus for gripping objects |
US6207638B1 (en) * | 2000-02-23 | 2001-03-27 | Pacifichealth Laboratories, Inc. | Nutritional intervention composition for enhancing and extending satiety |
JP2001346537A (ja) * | 2000-06-07 | 2001-12-18 | Sansei Shokuhin Kk | 果実外皮を用いた機能性食品およびその製造方法 |
JP4889846B2 (ja) * | 2000-06-20 | 2012-03-07 | キリンフードテック株式会社 | 高甘味度甘味料含有組成物 |
US6384087B1 (en) * | 2000-09-01 | 2002-05-07 | University Of Tennesseee Research Corporation, Inc. | Materials and methods for the treatment or prevention of obesity |
US7704979B2 (en) * | 2000-09-01 | 2010-04-27 | The University Of Tennessee Research Foundation | Materials and methods for the treatment or prevention of obesity |
WO2002071854A1 (en) * | 2001-03-09 | 2002-09-19 | Unilever N.V. | Fermented milk product |
US20030118662A1 (en) * | 2001-12-05 | 2003-06-26 | Glanbia Foods, Inc. | Therapeutic uses of milk mineral fortified food products |
US20030165574A1 (en) * | 2002-03-01 | 2003-09-04 | Ward Loren Spencer | Compositions and methods for treatment of body weight conditions |
US7790670B2 (en) * | 2002-03-01 | 2010-09-07 | Glanbia Nutritionals (Ireland) Ltd. | Compositions and methods for treatment of body weight conditions |
JP2005538704A (ja) * | 2002-07-01 | 2005-12-22 | ユニリーバー・ナームローゼ・ベンノートシヤープ | 満腹誘導組成物 |
US7399496B2 (en) * | 2003-02-07 | 2008-07-15 | Glanbia Nutritionals (Ireland) Limited | Hydrolyzed whey protein compositions |
JP3979306B2 (ja) * | 2003-02-25 | 2007-09-19 | 日本電気株式会社 | 無線端末装置および無線通信システム |
US6861073B2 (en) * | 2003-04-11 | 2005-03-01 | Paul Ling Tai | Dysfunctional satiety center syndrome and method of treatment therefor |
BRPI0508181A (pt) * | 2004-04-02 | 2007-08-07 | Univ Tennessee Res Foundation | componentes de laticìnio eficazes para a perda de gordura |
-
2003
- 2003-02-21 US US10/371,534 patent/US20030165574A1/en not_active Abandoned
- 2003-02-25 EP EP10011956A patent/EP2374507A1/en not_active Withdrawn
- 2003-02-25 EP EP10011587A patent/EP2316529A1/en not_active Ceased
- 2003-02-25 EP EP03709343A patent/EP1483023A1/en not_active Ceased
- 2003-02-25 BR BRPI0308141-9A patent/BR0308141A/pt not_active Application Discontinuation
- 2003-02-25 CN CNA038096668A patent/CN1649644A/zh active Pending
- 2003-02-25 KR KR10-2004-7013557A patent/KR20040105737A/ko not_active Application Discontinuation
- 2003-02-25 JP JP2003572638A patent/JP5586815B2/ja not_active Expired - Lifetime
- 2003-02-25 CA CA2477854A patent/CA2477854C/en not_active Expired - Lifetime
- 2003-02-25 KR KR1020107017076A patent/KR20100098721A/ko not_active Application Discontinuation
- 2003-02-25 AU AU2003213291A patent/AU2003213291A1/en not_active Abandoned
- 2003-02-25 MX MXPA04008476A patent/MXPA04008476A/es active IP Right Grant
- 2003-02-25 WO PCT/US2003/005797 patent/WO2003074129A1/en active Application Filing
-
2005
- 2005-03-29 US US11/091,924 patent/US20060067986A1/en not_active Abandoned
-
2010
- 2010-04-08 JP JP2010089453A patent/JP6041459B2/ja not_active Expired - Fee Related
-
2011
- 2011-11-07 US US13/290,344 patent/US20120052132A1/en not_active Abandoned
-
2014
- 2014-01-07 JP JP2014001185A patent/JP2014097997A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN1649644A (zh) | 2005-08-03 |
BR0308141A (pt) | 2006-06-13 |
US20120052132A1 (en) | 2012-03-01 |
AU2003213291A1 (en) | 2003-09-16 |
CA2477854C (en) | 2014-09-09 |
JP6041459B2 (ja) | 2016-12-07 |
JP2006507217A (ja) | 2006-03-02 |
WO2003074129A1 (en) | 2003-09-12 |
MXPA04008476A (es) | 2005-07-13 |
JP2010189412A (ja) | 2010-09-02 |
CA2477854A1 (en) | 2003-09-12 |
KR20040105737A (ko) | 2004-12-16 |
KR20100098721A (ko) | 2010-09-08 |
US20060067986A1 (en) | 2006-03-30 |
US20030165574A1 (en) | 2003-09-04 |
JP2014097997A (ja) | 2014-05-29 |
EP2316529A1 (en) | 2011-05-04 |
EP2374507A1 (en) | 2011-10-12 |
EP1483023A1 (en) | 2004-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5586815B2 (ja) | 乳鉱物およびカゼイン分画を用いる体重状態の治療のための組成物および方法 | |
US7790670B2 (en) | Compositions and methods for treatment of body weight conditions | |
US6468962B1 (en) | Nutritional intervention composition for enhancing and extending satiety | |
AU2003287974B2 (en) | Blood glucose regulating composition | |
PL184852B1 (pl) | Kompozycja na bazie składników soi | |
JP2005505500A5 (ja) | ||
JP7366540B2 (ja) | メタボリックシンドローム治療用栄養補助食品および食品組成物 | |
US20070172474A1 (en) | Dairy components effective for fat loss | |
US20030118662A1 (en) | Therapeutic uses of milk mineral fortified food products | |
US20070128252A1 (en) | Compositions and methods for treatment of body weight conditions | |
AU2006235407B2 (en) | Stable dairy components effective for fat loss | |
JP3560309B2 (ja) | カルシウム吸収促進栄養組成物 | |
JP2000139411A (ja) | イソフラボンとペプチドを組み合わせた食品及び飲料 | |
Upadhay et al. | In Touch |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080917 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080925 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090609 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090910 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091208 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100408 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100812 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20110114 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120131 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121023 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121029 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130604 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130903 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140225 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140523 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140723 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5586815 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |